$39 Million

Synta Pharmaceuticals

Follow-on Offering

Bookrunner, March 2015

Confidentially Marketed Public Offering

Developer of small molecule drugs for severe medical conditions. The company offers clinical and preclinical-stage drug candidates with mechanisms of action and novel chemical structures.